Orfiril Saft (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril Saft, is an anticonvulsant presented as an oral solution for oral use. It treats epilepsy and related seizure disorders in children and adults.\n\nGNH India supplies Orfiril Saft as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril Saft, a sodium valproate formulation, is used across several seizure‑related conditions and mood disorders.\n\n- Generalized tonic‑clonic seizures: reduces seizure frequency and severity.\n- Absence seizures: helps achieve seizure control in typical absence epilepsy.\n- Myoclonic seizures: diminishes myoclonic jerks and improves daily function.\n- Lennox‑Gastaut syndrome: lowers the number of drop attacks and improves quality of life.\n- Bipolar disorder (mood stabilization): assists in preventing manic episodes when prescribed by a psychiatrist.

Adverse reactions may occur with sodium valproate therapy and vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Weight gain\n- Tremor\n- Drowsiness or fatigue\n- Hair thinning or loss\n\nSerious or Rare Side Effects:\n- Hepatotoxicity (liver injury)\n- Acute pancreatitis\n- Thrombocytopenia or other blood dyscrasias\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Hyperammonemic encephalopathy\n- Fatal overdose in overdose situations.

When prescribing Orfiril Saft, clinicians should observe several safety measures.\n\n- Liver monitoring: assess hepatic enzymes before initiation and periodically during therapy.\n- Blood count monitoring: check platelet levels and complete blood count regularly.\n- Pregnancy caution: avoid use in pregnancy unless benefits outweigh risks, due to teratogenic potential.\n- Mitochondrial disorder warning: contraindicated in patients with known mitochondrial disease.\n- Dose adjustment: consider reduced dosing in hepatic or renal impairment.\n- Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sodium valproate may interact with several medicines, altering efficacy or safety.\n\nMajor Interactions (Avoid):\n- Carbamazepine: induces metabolism, lowering valproate plasma levels.\n- Phenobarbital: reduces valproate concentrations through hepatic enzyme induction.\n- Rifampicin: markedly decreases valproate exposure.\n- Other strong enzyme inducers (e.g., phenytoin, primidone): may render valproate ineffective.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: valproate can increase INR, requiring closer anticoagulation monitoring.\n- Lamotrigine: combined use raises risk of severe skin reactions.\n- Topiramate: additive central nervous system depression may occur.\n- Oral contraceptives: valproate may reduce hormonal efficacy, necessitating alternative contraception.